查詢結果分析
相關文獻
- Radiotherapy for Intracranial Germinoma: Treatment Modalities and Clinical Outcome
- Malignant Primary Extragonadal Germ Cell Tumors of Mediastinum--An Analysis of Clinical and Radiological Features in 15 Cases
- 一位鼻咽癌病患放射線合併化學治療之護理經驗
- 放射線及化學治癌藥物保護劑
- Treatment of a Pineal Yolk Sac Tumor: Report of One Case
- Concurrent Chemoradiation with Weekly Cisplatin Plus Systemic Adjuvant Chemotherapy for Locally Advanced Esophageal Cancer--A Pilot Study
- 惡性縱膈腔生殖細胞瘤之放射線治療
- 補氣藥對於化學或放射線治療後病人免疫力之作用
- 放射線治療合併化學治療的原則
- 治療癌症,營養作伴!
頁籤選單縮合
題名 | Radiotherapy for Intracranial Germinoma: Treatment Modalities and Clinical Outcome=放射線治療對於顱內生殖細胞瘤之臨床結果與治療方式分析 |
---|---|
作者 | 王裕仁; 許峯銘; 陳育瑄; 蔡巧琳; 陳婉瑜; 成佳憲; 郭頌鑫; Wang, Yu-jen; Hsu, Feng-ming; Chen, Yu-hsuan; Tsai, Chiao-ling; Chen, Wan-yu; Cheng, Jason Chia-hsien; Kuo, Sung-hsin; |
期刊 | 放射治療與腫瘤學 |
出版日期 | 20140600 |
卷期 | 21:2 2014.06[民103.06] |
頁次 | 頁111-119 |
分類號 | 416.36 |
語文 | eng |
關鍵詞 | 生殖細胞瘤; 放射線治療; 化學治療; 全腦脊髓照射; 全腦室; Germinoma; Radiotherapy; Chemotherapy; Craniospinal irradiation; Whole-ventricle; |
中文摘要 | 目的:我們用回溯性分析顱內生殖細胞瘤的臨床病理特徵,治療方式包括單純放射線治療(RT),及引導式化學治療併放射線治療(CRT)及其臨床預後。研究方法與材料:於2006年到2012年,總共收錄20位經病理組織確認,並在本院接受治療並有追蹤資料的顱內生殖細胞瘤的病人。其中16位病人接受合併化學治療與放射線治療(CRT),4位病人接受單純放射線治療(RT)。對於接受CRT的病人,他們先接受1到5個療程的引導式化學治療後,接受局部放射線治療(全腦室或是腫瘤區域)或者是全腦脊髓照射。放射線治療之劑量與照野大小因腫瘤位置,腫瘤對於化學治療之反應和脊髓受侵犯之狀態而定。在20位病人中,有13位病人採用三度空間放射線治療技術進行治療,其他7位接受全腦脊髓照射的病人,則採用螺旋刀治療技術。結果:本研究包括18位男性與2位女性,年齡中位數為14歲,範圍為7至29歲。追蹤時間平均中位數為34個月,其3年的無疾病存活率為90%,而整體存活率為100%。對於單純接受放射線治療的病人,全腦脊髓照射劑量為30.6格雷(Gy),每日照射1.8格雷,若無腦脊髓照射時,全腦室及腦下腺神經部照射劑量為30格雷,每日照射2格雷,再針對腫瘤區域加強劑量到中位數劑量50格雷(46.5-50.4格雷)。而對於接受化學治療及放療的病人,全腦脊髓照射劑量中位數為24格雷(21.6-30.6格雷),每日接受1.5至1.8格雷,之後再針對腫瘤區域加強劑量到中位劑量45格雷(24-50.4格雷)。單純接受放射線治療的病人中沒有復發的情況,然而2位接受化放療但沒有接受全腦脊髓照射的病人則發生脊椎區域復發。結論:我們的研究成果顯示對於顱內生殖細胞瘤而言,不論病患腦脊髓液是否測得β-HCG,前導式化療搭配較少劑量及較小照射範圍的放射線治療,皆可達到良好的疾病控制與預後。 |
英文摘要 | Purpose: We retrospectively analyzed the clinicopathologic features and treatment modalities, including radiotherapy (RT) alone and induction chemotherapy followed by RT (CRT), and the clinical outcomes of intracranial germinoma. Methods and Materials: A total of 20 patients diagnosed with tissue-confirmed intracranial germinoma between 2006 and 2012 and available follow-up data were included in this study. Sixteen patients underwent CRT and 4 underwent RT alone. CRT involved one to five cycles of upfront chemotherapy followed by limited-field (whole ventricle plus primary tumor boost) or extended-field RT (craniospinal irradiation [CSI] followed by limited-field), for which the RT field and dose depended on the tumor location, response to chemotherapy, and metastatic status. Among them, 13 patients received limited or extended-field RT with 3-dimensional (3D) conformal radiotherapy (3D-CRT), and 7 patients received CSI accompanied by helical tomotherapy. Results: This study consisted of 18 male and 2 female patients, with a median age of 14 years (7-29 y). After a median follow-up of 34 months, the 3-year disease-free survival rate and overall survival (OS) rate were 90% and 100%, respectively. For the RT alone group, the CSI was delivered with a tumor dose of 30.6 Gy in fractions of 1.8 Gy/d, whole-ventricle and neurohypophysis involved administering 30 Gy in fractions of 2 Gy/d if no CSI was used. Finally, the tumor was boosted to receive a total median dose of 50 Gy (46.5-50.4 Gy), whereas for the CRT group, the entire brain and/or spine received a median of 24 Gy (21.6-30.6 Gy) in fractions of 1.5-1.8 Gy/d, and the tumor was boosted to a total median dose of 45 Gy (24-50.4 Gy). No recurrences developed in patients treated using extended RT; however, 2 patients treated with CRT, but not with CSI, developed spinal relapse. Conclusion: Our results indicate that induction chemotherapy accompanied by dosereduced and volume-reduced RT resulted in effective disease control and prognosis for intracranial germinoma, including β-HCG secreting germinoma. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。